SBIR/STTR Research Award

MICROWAVE-ENHANCED LUMINESCENCE TO DETECT GROWTH FACTORS

Award identifier e24376842d3043a7bc1425e51ed63e7cbd6d26db7ecea7f727abf4677777251fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$269,930

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MIRARI BIOSCIENCES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): "Microwave Chemiluminescence"(MCL) is a broad new enabling technology that promises to greatly improve the speed and convenience of numerous types of chemiluminescence (CL)-based analyses. MCL is the first use of targeted microwave chemistry in the field of bioanalyses. Microchip-based MCL assays combine the exquisite specificity of antibodies or hybridized nucleic acids with the focused heat energy of microwave radiation. Microwaves raise the temperature of the microchip surface, initiating and greatly accelerating the rates of surface-bound CL reporter reactions. MCL instrumentation and chips will be developed for the overall goal of increasing the productivity of cancer research. In Phase I, we will demonstrate the technology using TNFalpha as the first immunoassay analyte. Further research, Phases II and III, will focus on multi-analyte panels measuring angiogenic growth factors. Studies of angiogenesis are critical to the understanding and treatment of solid tumors and such panels using MCL detection will fill an unmet need in cancer research laboratories. Moreover, an angiogenesis factor panel is a logical entry point to our long-term goal of greatly expanded arrays of cancer-related analytes, including endogenous angiogenesis inhibitors, growth factor receptors, and signal transduction proteins. PROPOSED COMMERCIAL APPLICATION: The overall research objective is to develop a new analytical technology that will assist cancer researchers by bringing the sensitivity chemiluminescence sensitivity to a convenient microchip array format. A panel of chip-based immunoassays for angiogenesis factors will be developed to assist basic and clinical researchers in cancer research and drug discovery. Future work will expand the technology to other applications in protein and nucleic acid analysis.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.